





Analysis of circulating microRNAs and their post-transcriptional modifications in 
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In this paper, an on-line solid-phase extraction capillary electrophoresis-mass 
spectrometry (SPE-CE-MS) method is described for the purification, preconcentration, 
separation, and characterization of endogenous microRNA (miRNA) and their post-
transcriptional modifications in serum. First, analysis by CE-MS was optimized using a 
standard mixture of hsa-miR-21-5p (miR-21-5p) and hsa-let-7g-5p (let-7g-5p). For 
SPE-CE-MS, a commercial silicon carbide (SiC) resin was used to prepare the 
microcartridges. Under the optimized conditions with standards, the microcartridge 
lifetime (>25 analyses) and repeatability (2.8% RSD for the migration times; 4.4 and 
6.4% RSD for the miR-21-5p and let-7g-5p peak areas, respectively) were good, the 
method was linear between 25 and 100 nmol·L-1, and the limit of detection (LOD) was 
around 10 nmol·L-1 (50 times lower than by CE-MS).  
In order to analyze human serum samples, an off-line sample pretreatment based 
on phenol/chloroform/isoamyl alcohol (PCA) extraction was necessary prior to SPE-
CE-MS. The potential of the SPE-CE-MS method to screen for B-cell chronic 
lymphocytic leukemia (CLL) was demonstrated by an analysis of serum samples from 
healthy controls and patients. MicroRNAs, specifically miR-21-5p and a 23 nucleotide 
long 5’-phosphorylated miRNA with 3’-uridylation (iso-miR-16-5p), were only 





MicroRNAs (miRNAs) are a class of single-stranded, non-protein-coding RNAs 
that are19–23 nucleotides long. The function of a miRNA is to control gene expression 
post-transcriptionally, regulating messenger RNA (mRNA) by binding to the 3′ 
untranslated region (3′ UTR) of the target mRNA1. miRNAs play a major role in a wide 
range of normal cellular processes, including cell proliferation, development, and 
apoptosis2. Circulating miRNAs have been found in the extracellular environment, 
including in various biological fluids, such as the blood, saliva, and urine of both 
diseased and healthy people. These extracellular miRNAs are packaged in extracellular 
vesicles3 or associated with RNA-binding proteins4,5, leading to high stability and 
resistance to endogenous RNase activity, extreme temperature, and pH6.  
Deregulation of miRNAs has been associated with different diseases, such as 
cardiovascular diseases, diabetes, aberrant immune function, and especially cancer7. In 
comparison with longer biomarker molecules, miRNAs present several advantages: they 
have relatively smaller numbers of candidate sequences and higher stability due to their 
smaller size, which leads to an improved robustness of detection. Furthermore, they are 
detectable in accessible biofluids, such as serum. For these reasons, miRNAs are great 
candidates as minimally invasive biomarkers for early disease diagnosis, prognosis, and 
treatment outcome for different diseases8. In this sense, miR-21-5p is one of the most 
frequently upregulated miRNAs in solid tumors, and its levels have been associated 
with relapse-free survival9,10.  
Several analytical methods have been developed for the detection of miRNAs and the 
most commonly used are Northern blotting11, microarrays12, and a two-step procedure 
of modified reverse transcription polymerase chain reaction followed by quantitative 
PCR (RT-qPCR)13. The last method is very sensitive, but it is based on the indirect 
detection of complementary DNA. Furthermore, the above-mentioned methods are not 





phosphorylation and dephosphorylation, or unexpected isoforms with differing ends due 
to trimming or nucleotide additions14. These modifications have been reported to affect 
the stability of miRNA and be a mechanism for the regulation of miRNA activity15. 
Thus, the development of direct analytical methods able to obtain information regarding 
post-transcriptional modifications of miRNA is of great interest. In this respect, 
capillary electrophoresis-mass spectrometry (CE-MS) is a highly efficient technique for 
the separation and characterization of biomolecules; it is generally applied in the field of 
proteomics and metabolomics and less in genomics because of the emergence of next-
generation sequencing techniques (NGS)16–20. CE-MS has rarely been used for the 
analysis of small RNAs, although it allows direct, label-free, multiplex analysis and 
precise mass identification of post-transcriptional modifications of miRNAs21. Small 
RNAs can be isolated from biological fluids using commercially available kits and then 
analyzed by CE-MS. However, the small injection volumes typical of CE compromise 
the concentration sensitivity. The use of highly selective and sensitive mass 
spectrometers is often not enough for robust detection; consequently, CE-MS has often 
been combined with different electrophoretic and chromatographic techniques for the 
on-line preconcentration of the target analytes, such as sample stacking, 
isotachophoresis, or on-line solid-phase extraction (SPE-CE)22–27. In SPE-CE, a 
microcartridge with an appropriate sorbent is inserted near the inlet of the separation 
capillary to purify and preconcentrate the target analytes from a large volume of sample. 
SPE-CE-MS has been extensively applied for the analysis of small molecules (drugs, 
metabolites, etc.), peptides, and proteins using the silica or polymeric sorbents typically 
used in off-line SPE (e.g., C18)28–30 because of the versatility of these sorbents and their 
commercial availability. The use of other sorbents for improved selectivity, such as 





specific conditions required for the extraction and compatibility with on-line MS 
detection31–33. 
In recent years, different commercially available kits, based on SPE spin 
microcolumns used in combination with liquid-liquid extraction and precipitation, have 
been developed for miRNA isolation and purification from biological fluids. These 
multistep sample pretreatments are widely used prior to PCR-based analytical methods 
due to their excellent recoveries and simplicity of usage34–36. However, to the best of our 
knowledge, the on-line coupling of these SPE methods to a high-performance 
separation technique with MS detection has not yet been explored, although it may 
reduce manual handling and increase analysis throughput while obtaining valuable 
structural information. 
In this paper, for the first time, an SPE-CE-MS method for the purification, 
preconcentration, separation, and untargeted multiplex analysis of miRNAs from serum 
samples is described. The SPE-CE-MS analysis of miRNA was optimized using 
standards, and the figures of merit were compared with those of a previously developed 
sample stacking CE-MS method21. Subsequently, the applicability of the developed 
SPE-CE-MS method was demonstrated by the analysis of serum samples from healthy 
controls and patients with chronic lymphocytic leukemia (CLL), the most common type 







Materials and reagents 
 
All the chemicals used in the preparation of background electrolytes (BGEs) and 
solutions were of analytical-reagent grade or better. Acetic acid (glacial), ammonium 
hydroxide (25%), guanidinium chloride (≥99.0%), ortho-phosphoric acid (85%), and 
sodium hydroxide (≥99.0%) were purchased from Merck (Darmstadt, Germany). 
Acetonitrile (LC-MS), 96% ethanol and methanol (LC-MS) were supplied by Panreac 
AppliChem (Barcelona, Spain). Propan-2-ol (LC-MS) was purchased from Scharlau 
(Barcelona, Spain). Ammonium acetate (NH4Ac, ≥99.999%), ammonium bicarbonate 
(for LC-MS), chloroform (≥99.0%), and phenol/chloroform/isoamyl alcohol mixture 
(PCA, 25:24:1) were supplied by Sigma-Aldrich (Madrid, Spain). The TRIzol Reagent 
was purchased from Thermo Fisher Scientific (Barcelona, Spain). Synthetic miRNA 
hsa-miR-21-5p (miR-21-5p), hsa-let-7g-5p (let-7g-5p), and hsa-miR-16-5p with 3’-
uridylation (iso-miR-16-5p) were purchased from IDT (Coralville, IA, USA). 
 
Electrolyte solutions, sheath liquid, miRNA standards and serum samples. 
 
All the solutions were stored in plastic bottles to minimize cation-adduct 
formation due to the glass-bottle Na+ and K+ leaching from and were degassed for 10 
min by sonication before use. The optimized BGE for the CE-MS and SPE-CE-MS 
separation contained 25 mM NH4Ac and was adjusted to pH 8.0 with ammonium 
hydroxide. The BGE was passed through a 0.20 µm nylon filter (Macherey-Nagel, 





propan-2-ol/water with 2 mM NH4Ac and was delivered at a flow rate of 3.3 µL·min
-1 
by a KD Scientific 100 series infusion pump (Holliston, MA, USA).  
Stock solutions (100 µmol·L-1) of each miRNA were stored in a freezer at -20ºC. 
The concentrations of these standard solutions were confirmed by measuring the 
absorbance at 260 nm (10 mm path length) using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific, Rockford, IL, USA). Working standard solutions were 
prepared from the stock solutions by dilution in water and were stored in the fridge at 
5ºC when not in use. 
Human serum samples and data from donors were provided by the INCLIVA 
BioBank (PT13/0010/0004; B.0000768 ISCIII), integrated in the Valencian Biobanking 
Network and the Spanish National Biobanks Network. They were processed following 
standard operating procedures with the appropriate approval of the Ethical and 
Scientific Committees. Three healthy donor serum samples and three CLL serum 
samples from patients with stage IV of the disease were analyzed. All the samples 
corresponded to males and females aged between 75 and 85 years. Serum aliquots were 
stored in a freezer at -80ºC. Healthy and CLL samples were thawed and separately 




pH measurements were made with a Crison 2002 potentiometer and 52-03 
electrode (Crison Instruments, Barcelona, Spain).  
Centrifugal filtration was carried out at 25ºC in a cooled Rotanta 460 centrifuge 








Fused silica capillaries were supplied by Polymicro Technologies (Phoenix, AZ, 
USA). All CE-MS experiments were performed in a 7100 CE coupled with an 
orthogonal G1603A sheath-flow interface to a 6220 oa-TOF LC/MS spectrometer 
(Agilent Technologies, Waldbronn, Germany). 
ChemStation and MassHunter softwares (Agilent Technologies) were used for 
the CE and TOF mass spectrometer control, data acquisition and integration, and mass 
spectrum deconvolution. The TOF mass spectrometer was operated in negative 
electrospray ionization mode (ESI–) and the optimized parameters are presented in the 
Supporting Information. 
Separations were performed at 15°C in a 72 cm long (LT) × 75 µm i.d. × 365 µm 
o.d. capillary. All capillary rinses were performed at high pressure (930 mbar). For new 
ones and between workdays, the capillaries were flushed with 1 M NaOH (15 or 5 min), 
water (15 or 10 min), and BGE (30 or 15 min) off-line to avoid the unnecessary 
contamination of the MS system. The samples were hydrodynamically injected at 50 
mbar for 10 s, and a separation voltage of +20 kV (normal polarity, cathode in the 
outlet) was applied. The autosampler was kept at 10°C using an external water bath 
(Minichiller 300, Peter Huber Kältemaschinenbau AG, Offenburg, Germany). Between 
consecutive runs, the capillary was conditioned by flushing with water (2 min) and BGE 
(2 min).  
 
Sample stacking CE-MS 
 
An electrophoretic preconcentration CE-MS method for the analysis of miRNA, 
described elsewhere21, was adapted to our specific CE-MS setup. Separations were 





BGE of 25 mM NH4Ac, adjusted to pH 6.0 with acetic acid. All capillary rinses were 
performed at high pressure (930 mbar). Before each injection, the capillary was rinsed 
with water (10 min) and BGE (3 min). Samples were injected at 930 mbar for 4 min (≈ 
2.2 µL, according to the Hagen–Poiseuille equation38), and then the long plug of sample 




The silicon carbide (SiC) resin was obtained from commercial microRNA 
purification kit spin columns (Norgen Biotek Corporation, Thorold, Canada). 
Construction of the microcartridge or analyte concentrator was carried out as 
described elsewhere with little modifications31,39,40. The inlet end was prepared by 
connecting the microcartridge (0.7 cm LT × 250 µm i.d. × 365 µm o.d. capillary) with a 
plastic sleeve to a previously conditioned inlet capillary (7.5 cm LT × 75 µm i.d. × 365 
µm o.d.). The microcartridge was completely filled by vacuum with the SiC particles. 
Another plastic sleeve was connected to the microcartridge, and a small piece of cotton 
(approximately 1 mm) was introduced in the plastic tube before connecting the 
separation capillary (64.5 cm LT × 75 µm i.d. × 365 µm o.d.). This cotton frit prevented 
the SiC particles from leaking, which had promoted current instability or breakdown 
and poor reproducibility. Samples were hydrodynamically introduced at 930 mbar for 5 
min (60 µL). A final flush for 40 s with BGE eliminated nonretained molecules and 
equilibrated the capillary before the electrophoretic separation. All these steps were 
performed by switching off the nebulizer gas and the ESI capillary voltage to prevent 
the entrance of contaminants into the MS. Then, both were switched on, a small volume 
of eluent with 60% (v/v) acetonitrile (ACN) was injected at 50 mbar for 10 s (50 nL); 





compensate for the microcartridge counter-pressure. Between consecutive runs, the 
capillary was rinsed for 4 min with water. 
Before SPE-CE-MS, the serum samples were extracted with PCA or the TRIzol 
Reagent, both of which were followed by chloroform extraction. The detailed procedure 
is presented in the Supporting Information. 
 
Quality parameters  
The details regarding the estimation of the limit of detection (LOD), limit of 
quantification (LOQ), repeatability of migration time and peak area, linearity, and 
microcartridge lifetime in CE-MS ands SPE-CE-MS are given in the Supporting 
Information. 
 




CE-MS was optimized by analyzing standard solutions of the synthetic miR-21-
5p and let-7g-5p miRNAs (Table S-1A). 
Most MS studies on nucleic acids use ESI-, because it yields a better signal for 
such acidic compounds21,41,42. However, because the phosphate groups of the miRNAs 
have cation-binding sites, clusters corresponding to Na+ and K+ adducts are typically 
detected in the mass spectrum, decreasing the signal of the expected [M-nH]n- molecular 
ions. In order to increase the sensitivity of the detection of miRNA in ESI– and to 
decrease cation adduct formation, several BGE and sheath liquid compositions were 
tested. In general, an effective method to minimize alkali adduct formation is the 





obtained with BGEs of ammonium acetate. Different BGE concentrations and acidities 
were tested at 10, 25, and 50 mM NH4Ac and at pHs 6.0 and 8.0, adjusted with acetic 
acid and ammonium hydroxide, respectively. The lowest adduct formation and highest 
sensitivity were obtained with a BGE of 25 mM NH4Ac at pH 8.0, in contrast to a 
previous study that reported a BGE of 25 mM NH4Ac at pH 6.0 for the analysis of 
miRNA by sample stacking CE-MS21. This BGE was always freshly prepared in plastic 
tubes to minimize cation adduct formation due to the leaching of Na+ and K+ from glass 
bottles. 
Different hydroorganic mixtures were also tested as sheath liquids, such as 
propan-2-ol, methanol, and acetonitrile at 60 and 80% (v/v). The highest sensitivity for 
miRNA detection was obtained with 80% (v/v) propan-2-ol (Figure S-1A). NH4OH 
(0.5%, v/v) was also added to this mixture to improve miRNA ionization, but the 
sensitivity was lower than with ammonium salts as additives. The optimized sheath 
liquid contained 80% (v/v) propan-2-ol and 2 mM NH4Ac, as in the Sample Stacking 
CE-MS method indicated before21, which showed better results than those containing 1, 
5, and 10 mM NH4Ac.  
As an example, Figure 1 shows the extracted ion electropherogram (EIE) and 
mass spectrum of a 5000 nmol·L-1 standard mixture of miR-21-5p and let-7g-5p in the 
optimized conditions. Both miRNA comigrated but showed molecular ions with 
different m/z values because of the molecular-mass differences. The most abundant ion 
was the [M-5H]5-, and some Na+ and K+ adducts were still detected ([M-6H+Na]5- and 
[M-6H+K]5-). Under these conditions, the LOD of the CE-MS method was 500 nmol·L-
1 for both miRNAs. 
 






Before exploring SPE-CE-MS, we adapted the sample stacking CE-MS method 
previously described for the analysis of miRNAs to the specific instrumental setup used 
in this study21. Sample stacking preconcentration during CE-MS was achieved by 
dissolving the sample in water, which had a lower conductivity than the BGE. A large 
volume of sample was injected hydrodynamically into the capillary between two plugs 
of BGE. When the separation voltage was applied, focusing and preconcentration of the 
ions happened at the narrow zone of the interface between the sample solution and the 
BGE because of a change in electrophoretic velocity due to a difference in the 
conductivities and, hence, the electric field.  
As an example, Figure 2 shows the analysis of a 250 nmol·L-1 standard mixture of miR-
21-5p and let-7g-5p in the adapted conditions. As expected from the results of the 
previous study21, migration times were 5 times higher using sample stacking than by 
conventional CE-MS (Figure 2A), and the mass spectrum showed the same ion clusters 
as by CE-MS (compare Figures 2B and 1B). The LOD of the sample stacking CE-MS 
method adapted to our instrumental setup was 50 nmol·L-1, 10 times lower than that by 
CE-MS, 500 nmol·L-1. A slightly lower LOD (20 nmol·L-1) was obtained by sample 
stacking CE-MS in the original study21, probably because of the better sensitivity of the 
mass spectrometer used in that case. Sample stacking allows a remarkable 
preconcentration factor, and in that study, it was demonstrated that it was possible to 
analyze miRNA from cancer serum samples21. As an alternative, in this study we 
investigated SPE-CE-MS to further enhance sensitivity, while reducing manual 








The SiC resin from the spin microcolumns of the Norgen microRNA isolation 
kit was used to prepare the on-line SPE-CE microcartridges. The literature provided by 
the manufacturer cited better recoveries and linearities on miRNA purification than with 
silica-based or traditional phase-separation methods44. Another important aspect of the 
SiC resin was the small particle size, which facilitated packing the on-line 
microcartridges. The starting point for the optimization of the SPE-CE-MS 
methodology was the procedure recommended by the manufacturer, as well as on other 
procedures applied for the extraction of hydrophilic analytes, such as protein glycans, 
with graphitic carbon sorbents45,46.  
In SPE-CE-MS, after sample loading, the microcartridge located at the capillary 
inlet needed to be washed to eliminate nonspecifically retained molecules and also filled 
with BGE before the elution, separation, and detection. In preliminary studies using the 
optimized BGE for CE-MS (25 mM NH4Ac, pH=8.0), some miRNA elution was 
detected during the washing and filling step with BGE (930 mbar, 2 min). This miRNA 
leakage was detrimental to achieving optimal sensitivity. Different strategies were 
explored, but it was found through those studies that changes in NH4Ac concentration 
or pH and also ammonium phosphate and bicarbonate BGEs resulted in poorer 
performance. 
Several modifications in the pressure and duration of the washing and filling 
step were, therefore, evaluated while the total volume of the flushed solution was 
minimized (4.0 µL, approximately 1.3 capillary volumes). This step was performed at 
low pressure (100 mbar, 360 s)38, but lower sensitivities than those at high pressure (930 
mbar, 40 s)38 were obtained. Several other alternatives were explored, including the use 
of guanidinium chloride (<1 M) or alcohols, but the results were not better than those 
obtained with this fast and short washing and filling step. In the first case, the remaining 





case, despite the manufacturer’s recommendation of the use of alcohols to increase 
miRNA retention by the SiC sorbent, methanol, ethanol, and propan-2-ol at 
concentrations between 10% and 70% (v/v) in the miRNA standard solutions or in the 
washing step promoted lower repeatability. This was probably because of the difficulty 
in rehydrating the sorbent or miRNA precipitation. In general, protocols for off-line 
miRNA extraction using spin columns include a drying step after sample loading and 
washing to evaporate the organic solvents. In SPE-CE-MS, we attempted to dry the 
microcartridge with air after sample loading and washing, prior to filling it with BGE. 
However, this procedural modification was discarded because bubbles were generated 
within the microcartridge, and electrophoretic separation was compromised.  
Regarding the elution, ACN and MeOH hydroorganic mixtures at 40, 60 and 
80% (v/v) were tested. The best sensitivity and repeatability of peak areas and migration 
times were obtained with a 60% (v/v) ACN (Figure S-1B) and no carry-over was 
observed between consecutive analyses. 
The sample loading time was studied by loading a 35 nmol·L-1 standard mixture 
of miR-21-5p and let-7g-5p at 930 mbar from 3 to 20 min. As can be seen in Figure 3, 
the maximum amount of miRNA was detected between 5 and 10 min. Between 15 and 
20 min of sample loading, analyte breakthrough caused a significant decrease of peak 
area. Hence, to reduce the total analysis time and to obtain the highest recoveries, a 
sample loading time of 5 min was selected as the best compromise for the rest of the 
experiments.  
Under the optimized conditions, consecutive analyses of the standard mixture 
were repeatable in terms of migration times and peak areas: (at 50 nmol·L-1, the percent 
RSDs (n=3) were 2.8 and 4.4% for miR-21-5p and 2.8 and 6.4% for let-7g-5p. As can 
be seen in Figure S-2, the method was satisfactorily linear (r2>0.97) between 25 and 100 





saturated, and there was not the expected increase in the peak areas. The LOD was 10 
nmol·L-1, which was an improvement of 50 and 5 times compared with those of the CE-
MS and sample stacking CE-MS methods, respectively. The LOQ was 25 nmol·L-1. The 
lifetimes of the microcartridges were around 25 analyses. As an example, Figure 4 
shows the SPE-CE-MS analysis of a 50 nmol·L-1 miR-21-5p and let-7g-5p standard 
mixture in the optimized conditions. In comparison with CE-MS (Figure 1), the 
migration times were similar, the number of theoretical plates (N) was slightly higher, 
and the same ions were detected in the mass spectrum. 
 
MicroRNA detection in cancer serum 
 
The SPE-CE-MS method optimized with standards was applied to the analysis 
of biological fluids. Considering that miRNA levels in serum and plasma samples are 
similar6 and that serum samples are more abundant in many clinical-sample 
repositories, serum samples were selected for miRNA profiling. Extracellular 
circulating miRNAs are found in the sera of both diseased and healthy people but at 
differing levels of concentration. miRNAs are resistant to endogenous RNase activity as 
well as extreme pHs and temperatures6,8 because they are contained within 
microvesicles or in protein and lipoprotein complexes9. For this reason, no miRNAs 
were detected when serum samples were loaded without any off-line pretreatment (e.g., 
addition of a lysis buffer or phenol solution). In addition, current instability and 
breakdown during the electrophoretic separation was observed because of saturation of 
the sorbent with the sample matrix components due to nonspecific retention. Therefore, 
an off-line sample pretreatment was required to inhibit RNase activity, dissociate the 
nucleocomplexes, precipitate proteins, and extract the miRNAs. Two extraction 





extraction in both cases. In addition, it was necessary to desalt the extracts because the 
retention of the miRNAs was compromised as a result of the high abundance of salts. 
Drop dialysis was performed because it was a simple, rapid, and highly effective 
method to remove the salts from the small volume samples47,48. 
The sample pretreatments were optimized with healthy control serum samples 
spiked with the standard miRNAs, miR-21-5p and let-7g-5p. The PCA-extraction 
procedure was selected because of the limited compatibility of the TRIzol Reagent with 
MS, due to the presence of high concentrations of chaotropic salts (i.e., guanidinium 
thiocyanate). In the optimized conditions, the sample pretreatment recoveries were high, 
approximately 85%, calculated by a comparison of the SPE-CE-MS analyses for a 50 
nmol·L-1 standard solution and a healthy control serum sample spiked at the same 
concentration. Consecutive analyses were repeatable in terms of migration times and 
peak areas (the percent RSDs (n=3) were 3.9 and 7.6% for miR-21-5p and 3.9 and 4.1% 
for let-7g-5p for the healthy control serum sample spiked at 50 nmol·L-1). Furthermore, 
the lifetimes of the microcartridges and LOD were similar to those with the standards 
(around 20 analyses and 10 nmol·L-1, respectively).  
With the optimized sample pretreatment and SPE-CE-MS method, in 
concordance with the previous study using the sample stacking CE-MS method21, no 
endogenous miRNAs were detected in the (unspiked) healthy control serum samples 
(Figure 5A,B), because of the extremely low abundance of miRNA in this type of 
samples. It is well-known that some miRNAs are up-regulated in sera from patients 
with different types of cancer9,49–52. CLL is a cancer of B-lymphocytes and is the most 
common type of leukemia in adults37. CLL derives from a combination of genetic 
(chromosomal abnormalities and gene mutations) as well as epigenetic (altered 
microRNA expression and DNA methylation) modifications53. Specific miRNA profiles 





SPE-CE-MS, in the analyzed CLL serum samples, two miRNAs were clearly detected 
at concentrations near the LODs (the EIEs and mass spectrum are shown in Figure 5C, 
D, respectively). The two miRNAs were tentatively identified using miRBase, which is 
a comprehensive database of miRNA sequences and expression 
(http://www.mirbase.org)55. The current version (miRBase 21) indexes 28645 miRNA 
entries and about 2000 sequences for humans. A screening of the most abundant 
miRNA species in CLL plasma and cell samples reported in the literature (Table S-2)56–
59 was performed, taking into account possible post-transcriptional modifications. The 
most likely possible candidates were miR-21-5p and miR-16-5p with 3′-uridylation 
(iso-miR-16-5p, Table S-1B). The analysis of a spiked CLL sample allowed the 
confirmation of the identities of the two miRNAs (Figure 5E,F). The detection of these 
two miRNA was in good agreement with the results reported for similar samples by 
sample stacking CE-MS and RT-qPCR21,60. miR-21-5p was the first serum miRNA 
biomarker discovered in the sera of CLL patients10; it is a representative oncogenic 
miRNA, and the overexpression of miR-21-5p as well as miR-16-5p in CLL has been 
previously reported21,60. In the future, the identities of the detected miRNAs could be 





We have developed an on-line SPE-CE-MS method for the purification, 
preconcentration, separation, and characterization of endogenous microRNAs and their 
post-transcriptional modifications in serum. Under the optimized conditions with 
standards, the microcartridge lifetime (around 25 analyses) and repeatability (2.8 and 





between 25 and 100 nmol·L-1, and the LOD was 10 nmol·L-1 (i.e., 50 and 5 times lower 
than by CE-MS and sample stacking CE-MS, 500 and 50 nmol·L-1, respectively). 
Regarding the analysis of the serum samples, it was necessary to apply an off-line 
sample pretreatment based on PCA extraction, but the recoveries for the miRNAs were 
>85%, and the performance of the SPE-CE-MS method was similar to that when the 
standards were used. Under the optimized conditions, it was possible to distinguish the 
healthy controls and CLL patients, because two endogenous miRNAs were detected at 
very low concentrations only in the diseased group. The results achieved show that 
SPE-CE-MS can be regarded as a promising technique for direct, high-throughput, 
sensitive, multiplex analyses capable of the preconcentration, quantification, and 
characterization of miRNA. The method also provides the unique structural information 
necessary for understanding the post-transcriptional regulation of miRNA function, and 
can be used in the discovery of new miRNA biomarkers for cancer and other diseases in 




Optimized MS parameters, serum-sample extraction, quality parameters, 
characteristics and molecular masses of the analyzed miRNAs, study of the sheath 
liquid in CE-MS and the eluent and linearity in SPE-CE-MS, and the list of miRNAs 
used for the screening of the CLL serum sample. 
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Figure 1. CE-MS for a 5000 nmol·L-1 miR-21-5p and let-7g-5p standard mixture. (A) 
Extracted ion electropherogram (EIE) and (B) mass spectrum. The number of 
theoretical plates (N) was calculated as N = 5.54 × (tm/w1/2)
2 where tm is the migration 
time, and w1/2 is the width at half the peak height. 
 
 
Figure 2. Sample stacking CE-MS for a 250 nmol·L-1 miR-21-5p and let-7g-5p 
standard mixture. (A) Extracted ion electropherogram (EIE) and (B) mass spectrum. 
The number of theoretical plates (N) was calculated as N = 5.54 × (tm/w1/2)
2 where tm is 







Figure 3. Plot of peak area of the eluted miR-21-5p (♦) and let-7g-5p (□) vs loading 
time at 930 mbar (35 nmol·L-1 standard mixture).  
 
 
Figure 4. SPE-CE-MS for a 50 nmol·L-1 miR-21-5p and let-7g-5p standard mixture. 
(A) Extracted ion electropherogram (EIE) and (B) mass spectrum. The number of 
theoretical plates (N) was calculated as N = 5.54 × (tm/w1/2)
2 where tm is the migration 







Figure 5. SPE-CE-MS for human serum samples. (A,C,E) Extracted ion 
electropherograms (EIEs) and (B,D,F) mass spectra  of (A,B) a healthy control sample, 
(C,D) a CLL-patient sample, and (E,F) a CLL-patient sample spiked with 50 nM miR-
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Optimized MS parameters 
The MS parameters, optimized by infusion experiments with a 5000 nmol·L-1 
let-7g-5p standard solution, were the following: capillary voltage 3500 V, drying gas 
temperature 350ºC, drying gas flow rate 6 L·min-1, nebulizer gas 7 psig, fragmentor 
voltage 225 V, skimmer voltage 70 V, OCT 1 RF Vpp voltage 300 V. Data were 
collected in profile at 1 spectrum/s between 100 and 3,200 m/z, with the mass range set 
to high resolution mode (4 GHz).  
 
Serum samples extraction 
According to the manufacturer’s instructions, 0.3 mL of serum was mixed with 
0.3 mL of PCA solution, centrifuged at 12,000 g and the aqueous phase (upper) was 
transferred to a new tube. To evaluate the extraction methodology, healthy control 
serum samples were spiked with 50 nmol·L-1 of the standard miRNAs, immediately 
after the first extraction to avoid degradation by endogenous serum RNases. Extraction 
with PCA was repeated twice more, until no protein was visible in the interface. Then, 
the aqueous phase was extracted with 0.2 mL chloroform to remove any residual 
phenol. Alternatively, for the extraction with the TRIzol Reagent, 0.3 mL serum was 
mixed with 3 mL of the TRIzol Reagent and 0.6 mL chloroform. In accordance to the 
manufacturer’s instructions, the extraction was repeated only once. In both cases, drop 
dialysis of the obtained aqueous phases (upper) was performed with MF-Millipore 
membrane filters of mixed cellulose esters, with average pore size diameter of 25 nm 
and 25 mm of diameter (Millipore, Molsheim, France).  The filter was floated with the 
glossy side up on a beaker with 50 mL of water. After 5 min for allowing the floating 
filter to wet completely, 100 µL of the sample extract was carefully placed on the center 







All quality parameters were calculated from data obtained by measuring peak 
area and migration time (tm) from the extracted ion electropherogram (EIE) considering 
the m/z of the most abundant miR-21-5p and let-7g-5p ions from the cluster resolved for 
the [M-5H]5-, and the sodium and potassium adducts [M-6H+Na]5- and [M-6H+K]5-. 
An estimation of the LODs was obtained by analyzing low-concentration 
standard mixtures (close to the LOD level, as determined from the approach based on 
S/N=3). LOQ was determined from the approach based on S/N=10. Reproducibility in 
SPE-CE-MS was evaluated as the relative standard deviation (percent RSD) of peak 
areas and tm. Linearity range was studied between 10 and 150 nmol·L
-1. The lifetimes of 







Table S-1. Characteristics and molecular masses of the (A) standard miRNAs, (B) miRNA tentatively identified by SPE-CE-MS in a CLL-patient 
serum sample. 
miRNA ID Sequence Modification 
m/z [M+2-5H]5- a) Calculated Mr ([M+2]) a) 
Theoretical  Observed Theoretical  Observed 
Error 
(ppm) 
(A) Standard miRNAs 
hsa-miR-21-5p 
(miR-21-5p) 
UAGCUUAUCAGACUGAUGUUGA 5’ phos 1415.5707 1415.5592 7082.89 7082.84 8 
hsa-let-7g-5p 
(let-7g-5p) 
UGAGGUAGUAGUUUGUACAGUU 5’ phos 1426.9677 1427.9537 7139.88 7139.81 10 
(B) miRNA tentatively identified in a CLL-patient serum sample 
hsa-miR-21-5p 
(miR-21-5p) 
UAGCUUAUCAGACUGAUGUUGA 5’ phos 1415.5707 1415.5485 7082.89 7082.78 15 
hsa-iso-miR16-5p UAGCAGCACGUAAAUAUUGGCGU 5’ phos, 3’-U 1488.9890 1488.9723 7449.98 7449.90 11 









Figure S-1. Effect of the organic solvent (A) in the sheath liquid (CE-MS, 5,000 
nmol·L-1 miR-21-5p standard) and (B) in the eluent (SPE-CE-MS, 50 nmol·L-1 miR-21-
5p standard). Peak area of the injected (CE-MS) or eluted miRNA (SPE-CE-MS). All 
measurements were performed in triplicate (standard deviation is given as error bars, 








Figure S-2. Plot of peak area of the eluted miR-21-5p (♦) and let-7g-5p (□) vs 
concentration of the loaded standard mixture (930 mbar, 5 min). Regression line and R2 







Table S-2. miRNAs reported in human B-cell chronic lymphocytic leukemia (CLL) 
plasma and cell samples used for the screening of endogenous miRNA in a CLL-patient 
serum sample by SPE-CE-MS (miRBase 21, http://www.mirbase.org 49). 
miRNA ID Sequence Length, nt 
hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG 22 
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG 22 
hsa-miR-16-2-3p CCAAUAUUACUGUGCUGCUUUA 22 
hsa-miR-20a-5p UAAAGUGCUUAUAGUGCAGGUAG 23 
hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA 22 
hsa-miR-23b-5p UGGGUUCCUGGCAUGCUGAUUU 22 
hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 22 
hsa-miR-29a-5p ACUGAUUUCUUUUGGUGUUCAG 22 
hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 23 
hsa-miR-101-5p CAGUUAUCACAGUGCUGAUGCU 22 
hsa-miR-106a-5p AAAAGUGCUUACAGUGCAGGUAG 23 
hsa-miR-146a-5p UGAGAACUGAAUUCCAUGGGUU 22 
hsa-miR-150-5p UCUCCCAACCCUUGUACCAGUG 22 
hsa-miR-155-5p UUAAUGCUAAUCGUGAUAGGGGU 23 
hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC 21 
hsa-miR-221-5p ACCUGGCAUACAAUGUAGAUUU 22 
hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC 23 
hsa-miR-222-5p CUCAGUAGCCAGUGUAGAUCCU 22 
hsa-miR-483-5p AAGACGGGAGGAAAGAAGGGAG 22 
hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG 22 
 
